IDEXX Laboratories (NASDAQ:IDXX) will post its quarterly earnings results before the market opens on Thursday, August 1st. Analysts expect IDEXX Laboratories to post earnings of $1.36 per share for the quarter.
IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Wednesday, May 1st. The company reported $1.17 EPS for the quarter, topping the consensus estimate of $1.04 by $0.13. The firm had revenue of $576.06 million for the quarter, compared to analyst estimates of $575.04 million. IDEXX Laboratories had a negative return on equity of 1,501.94% and a net margin of 17.33%. IDEXX Laboratories’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.01 EPS. On average, analysts expect IDEXX Laboratories to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.
IDEXX Laboratories stock opened at $286.05 on Wednesday. The business’s 50 day moving average is $278.15. The firm has a market cap of $24.43 billion, a price-to-earnings ratio of 67.15 and a beta of 0.86. The company has a quick ratio of 0.74, a current ratio of 1.01 and a debt-to-equity ratio of 14.81. IDEXX Laboratories has a one year low of $176.11 and a one year high of $292.17.
In other news, Director Rebecca M. Henderson sold 8,790 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $241.57, for a total value of $2,123,400.30. Following the completion of the sale, the director now directly owns 27,486 shares in the company, valued at approximately $6,639,793.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Michael Lane sold 1,812 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $245.41, for a total value of $444,682.92. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,721 shares of company stock worth $12,554,774. 2.70% of the stock is currently owned by corporate insiders.
A number of equities analysts have issued reports on IDXX shares. BidaskClub lowered Zai Lab from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 26th. Guggenheim reaffirmed a “buy” rating and issued a $95.00 target price (up from $90.00) on shares of VF in a research report on Thursday, May 23rd. Bank of America set a $300.00 target price on IDEXX Laboratories and gave the company a “buy” rating in a research report on Friday, June 21st. Canaccord Genuity reaffirmed a “speculative buy” rating and issued a GBX 70 ($0.91) target price on shares of Bacanora Lithium in a research report on Monday, July 1st. Finally, Stifel Nicolaus lowered Viveve Medical from a “buy” rating to a “hold” rating and cut their target price for the company from $3.00 to $1.00 in a research report on Monday, July 22nd. Eight analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $273.86.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Featured Story: NASDAQ Stock Market Explained
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.